ASCELIA PHARMA IS AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

Ascelia Pharma

ABOUT US

Our mission is to improve the life expectancy and quality of life for people living with cancer.

Our strategy is to develop and make available to patients a portfolio of differentiated, underappreciated and de-risked product candidates addressing unmet medical needs in cancer and cancer-related diseases.

Ascelia Pharma

Product pipeline

Lead candidate Mangoral (phase III ready) is an MRI imaging drug being developed for detection and localization of liver metastases.

Oncoral (in phase I) is a novel tablet-based irinotecan formulation, intended for treatment of advanced gastric (stomach) cancer.

Mangoral

Oncoral

News

PRESS RELEASE: Ascelia Pharma strengthens its oncology product portfolio

CMC Contrast AB acquires Oncoral Pharma Aps to further strengthen its product portfolio within oncology. In connection with the acquisition, the company is re-named to Ascelia Pharma AB.

PRESS RELEASE: Ascelia Pharma strengthens its board of directors to support international expansion

Ascelia Pharma is strengthening its current board of directors with the addition of Helena Wennerström and Hans Maier as the company prepares to continue its growth journey.